Singapore’s Health Sciences Authority (HSA) serves as the benchmark medical device regulator in Southeast Asia and is the preferred starting point for enterprises expanding into Southeast Asian markets. How do you select a registration pathway for Class C and D high-risk medical devices? What are the differences in review timelines across different channels? What are the most frequently raised deficiency questions? This CMEF public course breaks down the full registration workflow for high-risk medical devices in Singapore, aligned with official HSA guidance.
| Route | Core Eligibility | Target Review Timeline (Working Days) |
|---|---|---|
| Full | No reference market approvals; priority review available | B160 / C220 / D310; Priority Track: 104–202 |
| Abridged (Most Commonly Used) | At least 1 approval from a reference market, same intended use | B100 / C160 / D220 |
| Expedited | ECR-1: 1 reference market approval + 3 years of safe market historyEDR: ≥2 approvals from reference markets | C‑ECR: 120; D‑EDR: 180 |
| Immediate | Only for Class B devices, standalone medical mobile APPs (B/C); Not applicable for Class D | Listed directly in SMDR upon submission |
High-risk strategy:Secure approvals from ≥2 authoritative reference markets in advance to unlock the D‑EDR pathway, cutting review time by more than 4 months versus the Full route.
Eligible reference authorities: EU Notified Bodies, Australia TGA, Health Canada, Japan MHLW, US FDA, Malaysia MDA. Class I / exempt approvals do not qualify for pathway eligibility.
Recommendations for responding to HSA deficiencies:Restate the query → state conclusion → cite page numbers of supporting evidence → update labelling, IFU and full CSDT dossier in parallel to achieve closed-loop response.